Low Dose Naltrexone- Interview Preview with Dr. Sarah Zielsdorf and Linda Elsegood

/in , /by




In this interview, we review some of the remarkable benefits of low-dose naltrexone (LDN), including the surprising benefits of microdosed LDN. The two experts featured in this interview are Linda Elsegood, a Briton who founded the LDN Research Trust1 in 2004, and Dr. Sarah Zielsdorf, who has a medical practice in the Chicago area in the U.S.
Elsegood, who was diagnosed with MS in 2000, has been involved in LDN research and public education for 16 years. LDN is a powerful, safe and effective treatment for many autoimmune diseases, yet few, including most health care professionals, know anything about it. Remarkably, LDN may even be helpful in the fight against COVID-19, as it acts to normalize your immune system.2
Elsegood recently published a book on LDN called “The LDN Book, Volume Two: The Latest Research on How Low Dose Naltrexone Could Revolutionize Treatment for PTSD, Pain, IBD, Lyme Disease, Dermatologic Conditions and More.” Each chapter is written by a medical professional with clinical knowledge of the drug’s use. Zielsdorf is one of the contributing authors. Elsegood also hosts a radio show called The LDN Radio Show.3
In the interview, she tells the story of how she discovered LDN and the dramatic benefits she has experienced from it. In summary, beneficial effects became apparent after about three weeks on the drug and, after 18 months, her condition had significantly improved.

Watch the full interview here: https://youtu.be/olrqYWhKWtQ

Read the full article here:
https://articles.mercola.com/sites/articles/archive/2020/11/29/low-dose-naltrexone-benefits.aspx

Subscribe for the latest health news: http://bit.ly/2qLgWRW

Visit our website: http://bit.ly/2CA9VGn

Listen to our podcasts: http://bit.ly/2X87Z18

Subscribe to our Bitchute channel: http://bit.ly/2VoirD2

Find us on Social Media
MeWe: https://mewe.com/p-front/dr.josephmercola
Instagram: https://www.instagram.com/drmercola
Twitter: https://twitter.com/mercola


SOURCE